Monday, November 23, 2015

Expanded Access Programs 2016

Expanded Access Programs 2016
February 23-24, 2016 | Washington, DC
www.cbinet.com/expandedaccess

Current legislation is quickly paving the path for easier patient access to experimental, unapproved drugs. CBI’s Expanded Access Programs is the industry’s leading event dedicated to the nuances and complexities of designing and implementing early access programs. This multi-stakeholder event is focused on U.S. and global models for a variety of access management programs, including, but not limited to:

Expanded Access Programs, Early Access Programs, Compassionate Use Programs, Named Patient Programs and Managed Access Programs.

The FDA and a broad array of key stakeholders are coming together for an in-depth and meaningful discussion on Expanded Access Programs where the implications, prevailing policies and current industry approaches are discussed in detail. Don’t miss the opportunity to join your peers and share best practices around providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes.

Visit www.cbinet.com/expandedaccess for more information.

Speakers Include Representatives from:

FDA | National Organization for Rare Disorders (NORD) | Pfizer | Dyax Corporation |Prothena Biosciences, Inc. | King & Spalding LLP | Idis Managed Access | AstraZeneca | Biotechnology Industry Organization (BIO) | Ultragenyx Pharmaceutical | Max Cure Foundation, Inc. | Ax-S Pharma | ALS Emergency Treatment Fund | Halozyme Therapeutics, Inc. | Amgen | Canadian Organization for Rare Diseases (CORD)

Drug Channels readers will save $400 off of the standard registration rate when they use code SNH248.*

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

No comments:

Post a Comment